Logo image
Home Academic units
Sign in
Opioid use disorder and the COVID 19 pandemic: A call to sustain regulatory easements and further expand access to treatment
Journal article   Open access   Peer reviewed

Opioid use disorder and the COVID 19 pandemic: A call to sustain regulatory easements and further expand access to treatment

Traci C Green, Jeffrey Bratberg and Deborah S Finnell
Substance abuse, Vol.41(2), pp.147-149
2020
PMID: 32314951

Abstract

Betacoronavirus Buprenorphine - therapeutic use Continuity of Patient Care - legislation & jurisprudence Coronavirus Infections - complications COVID-19 Humans Methadone - therapeutic use Opioid-Related Disorders - complications Opioid-Related Disorders - therapy Opioid-Related Disorders - virology Pandemics Pharmacists Pneumonia, Viral - complications SARS-CoV-2 United States
We highlight the critical roles that pharmacists have related to sustaining and advancing the changes being made in the face of the current COVID-19 pandemic to ensure that patients have more seamless and less complex access to treatment. Discussed herein is how the current COVID-19 pandemic is impacting persons with substance use disorders, barriers that persist, and the opportunities that arise as regulations around treatments for this population are eased.

UN Sustainable Development Goals (SDGs)

This output has contributed to the advancement of the following goals:

#3 Good Health and Well-Being
url
https://doi.org/10.1080/08897077.2020.1752351View
Published (Version of record) Open

Metrics

16 Record Views

Details